Mu/Kappa Opioid Interactions in Rhesus Monkeys: Implications for Analgesia and Abuse Liability

Experimental and Clinical Psychopharmacology

Volumn 16, Issue 5, 2008, Pages 386-399

  Negus, S Stevens ^a   Schrode, Katrina ^a   Stevenson, Glenn W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

antinociception; drug interaction; kappa opioid agonist; mu opioid agonist; self administration

Indexed keywords

FENTANYL; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; BENZENEACETAMIDE DERIVATIVE; DIAGNOSTIC AGENT; NARCOTIC ANALGESIC AGENT; PYRROLIDINE DERIVATIVE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELF ADMINISTRATION; FEMALE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OPIATE ADDICTION; RHESUS MONKEY; ANIMAL; DRUG EFFECT; DRUG INTERACTION; HEAT; INSTRUMENTAL CONDITIONING; MACACA; PAIN ASSESSMENT; PSYCHOLOGICAL ASPECT; REINFORCEMENT;

ANALGESICS, OPIOID; ANIMALS; BENZENEACETAMIDES; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FENTANYL; HOT TEMPERATURE; MACACA MULATTA; MALE; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION;

EID: 54049098514     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0013088     Document Type: Article

References (51)

1. Arnold J.M., and Roberts D.C. A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacology, Biochemistry and Behavior 57 (1997) 441-447
2. Berger B., Rothmaier A.K., Wedekind F., Zentner J., Feuerstein T.J., and Jackisch R. Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex. British Journal of Pharmacology 148 (2006) 795-806
3. Bertalmio A.J., and Woods J.H. Differentiation between mu and kappa receptor-mediated effects in opioid drug discrimination: Apparent pA2 analysis. Journal of Pharmacology and Experimental Therapeutics 243 (1987) 591-597
4. Butelman E.R., Ko M.C., Sobczyk-Kojiro K., Mosberg H.I., Van Bemmel B., Zernig G., et al. kappa-Opioid receptor binding populations in rhesus monkey brain: Relationship to an assay of thermal antinociception. Journal of Pharmacology and Experimental Therapeutics 285 (1998) 595-601
5. Butelman E.R., Winger G., Zernig G., and Woods J.H. Butorphanol: Characterization of agonist and antagonist effects in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 272 (1995) 845-853
6. Craft R.M., and Dykstra L.A. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output. Journal of Pharmacology and Experimental Therapeutics 260 (1992) 327-333
7. Craft R.M., and Dykstra L.A. Agonist and antagonist activity of kappa opioids in the squirrel monkey: II. Effect of chronic morphine treatment. Journal of Pharmacology and Experimental Therapeutics 260 (1992) 334-342
8. Dykstra L.A. Behavioral and pharmacological factors in opioid analgesia. In: Seiden L.S., and Balster R.L. (Eds). Behavioral pharmacology: The current status (1985), Alan r. Liss, Inc, New York 111-129
9. Dykstra L.A. Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey. Journal of Pharmacology and Experimental Therapeutics 254 (1990) 245-252
10. Dykstra L.A., Gmerek D.E., Winger G., and Woods J.H. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. Journal of Pharmacology and Experimental Therapeutics 242 (1987) 413-420
11. Emmerson P.J., Clark M.J., Mansour A., Akil H., Woods J.H., and Medzihradsky F. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. Journal of Pharmacology and Experimental Therapeutics 278 (1996) 1121-1127
12. Emmerson P.J., Liu M.R., Woods J.H., and Medzihradsky F. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. Journal of Pharmacology and Experimental Therapeutics 271 (1994) 1630-1637
13. Funada M., Suzuki T., Narita M., Misawa M., and Nagase H. Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology 32 (1993) 1315-1323
14. Gerak L.R., Butelman E.R., Woods J.H., and France C.P. Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 271 (1994) 993-999
15. Gonzalez D., Riba J., Bouso J.C., Gomez-Jarabo G., and Barbanoj M.J. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug and Alcohol Dependence 85 (2006) 157-162
16. Gutstein H., and Akil H. Opioid analgesics. In: Brunton L., Lazo J., and Parker K. (Eds). The pharmacological basis of therapeutics. 11 ed. (2005), McGraw-Hill, New York 547-590
17. Hursh S.R., and Winger G. Normalized demand for drugs and other reinforcers. Journal of the Experimental Analysis of Behavior 64 (1995) 373-384
18. Malmberg A.B., and Yaksh T.L. Pharmacology of the spinal action of ketorolac, morphine, ST-91, U50488H, and L-PIA on the formalin test and an isobolographic analysis of the NSAID interaction. Anesthesiology 79 (1993) 270-281
19. Manchikanti L. National drug control policy and prescription drug abuse: Facts and fallacies. Pain Physician 10 (2007) 399-424
20. Mansour A., Khachaturian H., Lewis M.E., Akil H., and Watson S.J. Anatomy of CNS opioid receptors. Trends in Neurosciences 11 (1988) 308-314
21. Meisch R.A. Relative persistence of behavior: A fundamental measure of relative reinforcing effects. Experimental and Clinical Psychopharmacology 8 (2000) 333-349
22. Mello N.K., and Negus S.S. Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 286 (1998) 812-824
23. Miranda H.F., Puig M.M., Dursteler C., Prieto J.C., and Pinardi G. Dexketoprofen-induced antinociception in animal models of acute pain: Synergy with morphine and paracetamol. Neuropharmacology 52 (2007) 291-296
24. Mucha R.F., and Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berl) 86 (1985) 274-280
25. Narita M., Takahashi Y., Takamori K., Funada M., Suzuki T., Misawa M., et al. Effects of kappa-agonist on the antinociception and locomotor enhancing action induced by morphine in mice. Japanese Journal of Pharmacology 62 (1993) 15-24
26. Negus S.S., Burke T.F., Medzihradsky F., and Woods J.H. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: Antagonism by quadazocine. Journal of Pharmacology and Experimental Therapeutics 267 (1993) 896-903
27. Negus S.S., and Mello N.K. Opioid antinociception in ovariectomized monkeys: Comparison with antinociception in males and effects of estradiol replacement. Journal of Pharmacology and Experimental Therapeutics 290 (1999) 1132-1140
28. Negus S.S., Picker M.J., and Dykstra L.A. Interactions between mu and kappa opioid agonists in the rat drug discrimination procedure. Psychopharmacology (Berl) 102 (1990) 465-473
29. Negus S.S., Picker M.J., and Dykstra L.A. Interactions between the discriminative stimulus effects of mu and kappa opioid agonists in the squirrel monkey. Journal of Pharmacology and Experimental Therapeutics 256 (1991) 149-158
30. Negus S.S., Zuzga D.S., and Mello N.K. Sex differences in opioid antinociception in rhesus monkeys: Antagonism of fentanyl and U50,488 by quadazocine. J Pain 3 (2002) 218-226
31. O'Neill S.J., Collins M.A., Pettit H.O., McNutt R.W., and Chang K.J. Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice. Journal of Pharmacology and Experimental Therapeutics 282 (1997) 271-277
32. Pfeiffer A., Brantl V., Herz A., and Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 233 (1986) 774-776
33. Pick C.G., Paul D., and Pasternak G.W. Nalbuphine, a mixed kappa 1 and kappa 3 analgesic in mice. Journal of Pharmacology and Experimental Therapeutics 262 (1992) 1044-1050
34. Preston K.L., and Jasinski D.R. Abuse liability studies of opioid agonist-antagonists in humans. Drug and Alcohol Dependence 28 (1991) 49-82
35. Prisinzano T.E. Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sciences 78 (2005) 527-531
36. Remmers A.E., Clark M.J., Mansour A., Akil H., Woods J.H., and Medzihradsky F. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. Journal of Pharmacology and Experimental Therapeutics 288 (1999) 827-833
37. Sivachenko A., Kalinin A., and Yuryev A. Pathway analysis for design of promiscuous drugs and selective drug mixtures. Current Drug Discovery Technologies 3 (2006) 269-277
38. Stevenson G.W., Folk J.E., Rice K.C., and Negus S.S. Interactions between delta and mu opioid agonists in assays of schedule-controlled responding, thermal nociception, drug self-administration, and drug versus food choice in rhesus monkeys: Studies with SNC80 [(+)-4-[({alpha}R)-{alpha}-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and heroin. Journal of Pharmacology and Experimental Therapeutics 314 (2005) 221-231
39. Stevenson G.W., Linsenmayer D.C., Folk J.E., Rice K.C., and Negus S.S. Opioid interactions in rhesus monkeys: Effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociceptionn. Journal of Pharmacology and Experimental Therapeutics 307 (2003) 1054-1064
40. Tallarida R.J. Drug synergism and dose-effect data analysis (2000), Chapman and Hall/CRC, Boca Raton, FL
41. Tang A.H., and Collins R.J. Behavioral effects of a novel kappa opioid analgesic, U-50488, in rats and rhesus monkeys. Psychopharmacology (Berl) 85 (1985) 309-314
42. Todtenkopf M.S., Marcus J.F., Portoghese P.S., and Carlezon Jr. W.A. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl) 172 (2004) 463-470
43. Verborgh C.M., Camu F., and Meert T.F. Interaction between sufentanil and U-50488H with respect to antinociception and respiratory depression in rats. Acta Anaesthesiologica Scandinavica 41 (1997) 895-902
44. Vivian J.A., Deyoung M.B., Sumpter T.L., Traynor J.R., Lewis J.W., and Woods J.H. k-opioid receptor effects of butorphanol in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 290 (1999) 259-265
45. Vonvoigtlander P.F., Lahti R.A., and Ludens J.H. U-50,488: A selective and structurally novel non-Mu (kappa) opioid agonist. Journal of Pharmacology and Experimental Therapeutics 224 (1983) 7-12
46. Walsh S.L., Strain E.C., Abreu M.E., and Bigelow G.E. Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157 (2001) 151-162
47. Wessinger W.D. Approaches to the study of drug interactions in behavioral pharmacology. Neuroscience and Biobehavioral Reviews 10 (1986) 103-113
48. Winger G., Hursh S.R., Casey K.L., and Woods J.H. Relative reinforcing strength of three N-methyl-D-aspartate antagonists with different onsets of action. Journal of Pharmacology and Experimental Therapeutics 301 (2002) 690-697
49. Woods J.H., Young A.M., and Herling S. Classification of narcotics on the basis of their reinforcing, discriminative, and antagonist effects in rhesus monkeys. Federation Proceedings 41 (1982) 221-227
50. Woolverton W.L. Analysis of drug interactions in behavioral pharmacology. In: Thompson T., Dews P.B., and Barrett J.E. (Eds). Neurobehavioral pharmacology (1987), Erlbaum, Hillsdale, NJ 275-302
51. Xi Z.X., Fuller S.A., and Stein E.A. Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: An in vivo fast-cyclic voltammetry study. Journal of Pharmacology and Experimental Therapeutics 284 (1998) 151-161